Felycin®-CA1 is the First and Only Drug FDA Conditionally Approved for the Management of Ventricular Hypertrophy in Cats
PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional approval from the FDA for Felycin®-CA1 (sirolimus delayed-release tablets) sold under the PRN Pharmacal brand of its affiliated company Pegasus, today announced the product is now available via licensed veterinarians nationwide. PBI-Gordon Companies, Inc. confirms that Felycin®-CA1 is the only drug currently legally marketed under conditional approval from the Food and Drug Administration (FDA) for the management HCM in cats.
From Chicago’s Gold Coast to the Top of the World: Dr. Jen Remnes on Redefining Veterinary Medicine
Welcome to the March 2025 edition of Vet Candy Magazine, where we celebrate the incredible stories of veterinarians who are pushing boundaries, breaking stereotypes, and redefining what it means to be a modern vet. This month, we’re thrilled to feature Dr. Jen Remnes on our cover—a veterinarian, entrepreneur, adrenaline junkie, and inspiration to us all.